179 related articles for article (PubMed ID: 28545679)
1. Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all".
Marti JL; Morris LGT; Ho AS
Eur J Surg Oncol; 2018 Mar; 44(3):348-356. PubMed ID: 28545679
[TBL] [Abstract][Full Text] [Related]
2. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making.
Tuttle RM; Sabra MM
Oral Oncol; 2013 Jul; 49(7):676-83. PubMed ID: 23601564
[TBL] [Abstract][Full Text] [Related]
3. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma.
Moore MD; Postma E; Gray KD; Ullmann TM; Hurley JR; Goldsmith S; Sobel VR; Schulman A; Scognamiglio T; Christos PJ; Hassett E; Luick J; Whitehall D; Zarnegar R; Fahey TJ
World J Surg; 2018 Feb; 42(2):343-349. PubMed ID: 29058064
[TBL] [Abstract][Full Text] [Related]
4. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
5. Referral Practice for Radioactive Iodine Ablation (RAI) after ATA guidelines 2015: results from a Tertiary Cancer Care Centre.
Dhar H; Thiagarajan S; Yousuf A; Nayyar SS; Chaukar D
Eur Arch Otorhinolaryngol; 2020 Sep; 277(9):2521-2526. PubMed ID: 32240364
[TBL] [Abstract][Full Text] [Related]
6. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
7. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer.
Haymart MR; Banerjee M; Yang D; Stewart AK; Koenig RJ; Griggs JJ
Cancer; 2013 Jan; 119(2):259-65. PubMed ID: 22744940
[TBL] [Abstract][Full Text] [Related]
8. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
9. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
10. Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.
Deutschmann MW; Chin-Lenn L; Nakoneshny SC; Dort JC; Pasieka JL; Chandarana SP
J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):55. PubMed ID: 27793192
[TBL] [Abstract][Full Text] [Related]
11. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
12. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
13. Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma.
McDow AD; Shumway CM; Pitt SC; Schneider DF; Sippel RS; Long KL
Ann Surg Oncol; 2019 Nov; 26(12):4002-4007. PubMed ID: 31267301
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing radioiodine uptake after thyroid cancer surgery.
Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
[TBL] [Abstract][Full Text] [Related]
15. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
[TBL] [Abstract][Full Text] [Related]
16. Tailoring the approach to radioactive iodine treatment in thyroid cancer.
Mayson SE; Chan CM; Haugen BR
Endocr Relat Cancer; 2021 Sep; 28(10):T125-T140. PubMed ID: 34254949
[TBL] [Abstract][Full Text] [Related]
17. Surgeon training and use of radioactive iodine in stage I thyroid cancer patients.
Schuessler KM; Banerjee M; Yang D; Stewart AK; Doherty GM; Haymart MR
Ann Surg Oncol; 2013 Mar; 20(3):733-8. PubMed ID: 23224826
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients.
Choudhury S; Agrawal A; Pantvaidya G; Shah S; Purandare N; Puranik A; Rangarajan V
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):547-553. PubMed ID: 31707429
[TBL] [Abstract][Full Text] [Related]
19. Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015.
Park KW; Wu JX; Du L; Leung AM; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):1095-1101. PubMed ID: 29267880
[TBL] [Abstract][Full Text] [Related]
20. Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.
Wallner LP; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Lubitz C; Hawley ST; Haymart MR
J Clin Endocrinol Metab; 2021 May; 106(6):e2402-e2412. PubMed ID: 33687063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]